Dr. Louise Pilote to coordinate a new personalized medicine project, GOING-FWD - Dr. Louise Pilote to coordinate a new personalized medicine project, GOING-FWD - Research Institute MUHC
Newsletter - Banner
A new research challenge aimed at improving the health and well-being of men and women worldwide will involve the Research Institute of the McGill University Health Centre (RI-MUHC) for the next three years.
GOING-FWD is a data science, personalized medicine project funded by the Canadian Institutes of Health and Research (CIHR) and GENDER-NET+, which is part of the European EU H2020 initiative, for a total of approximately $1.65 million. GOING-FWD is led and coordinated at the RI-MUHC by Dr. Louise Pilote, James McGill Professor of Medicine, McGill University; Dr. Valeria Raparelli, Visiting Professor of Medicine at McGill University from Sapienza University of Rome; and Dr. Colleen Norris, Professor in Nursing, Medicine and Public Health Science, University of Alberta.
GENDER-NET+ aims to promote the integration of sex and gender analysis into research. This integration will yield new knowledge and insights that ultimately benefit both women and men.
A large volume of data gathered through a network of five countries (Austria, Canada, Cyprus, Spain and Sweden) will allow innovative algorithms to be created that will assist in implementing personalized interventions for the management of noncommunicable diseases, such as cardiovascular, chronic kidney or neurodegenerative diseases.
Scientific Summary of the Project
Background: Beyond biological sex, gender is increasingly recognized as a pivotal determinant of health. However, there are no standardized gender measurements. The authors of the study hypothesize that gender-related factors and their effect will vary substantially between countries and diseases.
Aims: The overarching aims of this large Consortium are to integrate sex and gender dimensions in applied health research, to evaluate their impact on clinical cost-sensitive outcomes and on patient-reported outcomes related to quality of life in noncommunicable diseases, including cardiovascular disease, metabolic disease, chronic kidney disease and neurological disease. The research team also aims to construct innovative ways to disseminate the application of gender measurement towards personalized approaches to chronic disease prevention, diagnosis and treatment.
Methods: With a five-country transatlantic network comprised of 30 investigators, the project will benchmark innovative solutions to measure gender in retrospective cohorts. Based on consensus, the researchers will develop a framework to identify gender-related factors, as well as cost-sensitive and patient-reported outcomes, and measure their associations in 32 accessible cohorts of patients affected by cardiovascular, chronic kidney and neurological diseases and metabolic syndrome. Large database analysis and, when appropriate, machine learning approaches will allow the derivation of pan- and within-country disease-specific gender scores, which will be validated through e-Health and m-Health applications in prospective disease groups. Educational modules will be developed to promote awareness, implementation and dissemination.
Innovation: As a five-country multidisciplinary Consortium with access to large granular databases, the project is uniquely positioned to harness an innovative methodology that will provide a framework to close gender gaps in chronic disease management and promote knowledge transfer in the scientific community and clinical practice.
For further information, please contact: GOINGFWD2019@outlook.com
—Published February 6, 2019